A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

Not yet recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2030

Study Completion Date

August 1, 2030

Conditions
Chronic Lymphocytic Leukemia
Interventions
OTHER

Observational

The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively

Trial Locations (1)

50924

University Hospital Cologne, Cologne

All Listed Sponsors
collaborator

GELLC (Grupo Español de Leucemia Linfocítica Crónica)

OTHER

collaborator

Nordic Lymphoma Group

NETWORK

collaborator

Polish Adult Leukemia Group

OTHER

collaborator

HOVON - Dutch Haemato-Oncology Association

OTHER

lead

German CLL Study Group

OTHER

NCT06792994 - A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG | Biotech Hunter | Biotech Hunter